首页 工具
登录
购物车
Fidexaban

Fidexaban

产品编号 T27318   CAS 183305-24-0
别名: CI-1031, BX-807834, PD-200022, CI1031, BX807834, ZK-807834

Fidexaban (CI1031) 是一种新型、强效、选择性和口服活性 Xa 因子抑制剂,在多种测定中均显示出抗血栓活性。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
Fidexaban Chemical Structure
Fidexaban, CAS 183305-24-0
规格 价格/CNY 货期 数量
1 mg ¥ 990 现货
5 mg ¥ 2,520 现货
10 mg ¥ 3,710 现货
25 mg ¥ 5,980 现货
50 mg ¥ 8,270 现货
100 mg ¥ 10,900 现货
千万补贴 助力科研
BCA蛋白浓度测定试剂盒限时半价
重组蛋白限时优惠
Doxorubicin hydrochloride限时半价
产品目录号及名称: Fidexaban (T27318)
点击图片重新获取验证码
选择批次  
纯度: 99.42%
纯度: 98.08%
TargetMol batch loading
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 Fidexaban (CI1031) is a novel, potent, selective and orally active factor Xa inhibitor that has demonstrated antithrombotic activity in a variety of assays
靶点活性 FXa (human):0.11 nM(Ki)
体外活性 CI-1031 (ZK-807834) is a novel, synthetic factor Xa (FXa) inhibitor with a Ki of 0.11 nM against human FXa. In human plasma in vitro, CI-1031 doubled PT and aPTT at 0.23 and 0.49 microM, respectively. Ex vivo plasma anti-FXa activity was also well correlated with plasma concentration of CI-1031 and with PT (r = 0.96 and 0.98, respectively).[2]
体内活性 CI-1031 (ZK-807834) doubled PT and aPTT at 0.23 and 0.49 microM, respectively. The in vivo antithrombotic effect of CI-1031 was evaluated in a veno-venous shunt model of thrombosis in anesthetized rabbits. After thrombus formation was verified in the first shunts, rabbits received either vehicle or CI-1031 intravenously (bolus injection of 60, 240, or 480 microg/kg followed by an infusion of 2, 8, or 16 microg/kg/min for 140 min, respectively). The second shunts were inserted after 20 min of infusion of CI-1031 or vehicle. CI-1031 dose-dependently prolonged time to occlusion (TTO) in the second shunts (35 +/- 21, 62 +/- 24, and 120 +/- 0 min for the three dose groups, respectively, vs. 10 +/- 1 min for vehicle). Thrombus mass (TM) was reduced in a dose-dependent manner by CI-1031 (42 +/- 7, 27 +/- 6, and 18 +/- 4 mg vs. 50 +/- 4 mg for vehicle). Maximal TM reduction was 70% with an IC(50) of 0.6 microg/ml. Among all the coagulation parameters tested, PT had the best correlation with plasma CI- 1031 concentration (r = 0.97). These results indicate that CI-1031, which is currently undergoing clinical evaluation, is an effective antithrombotic compound with a favorable efficacy-to-bleeding ratio. In addition, CI-1031 concentration in plasma can be monitored using PT or anti-Xa assays, thereby providing reliable methods to ensure safe and accurate dose titration of CI-1031.[2]
别名 CI-1031, BX-807834, PD-200022, CI1031, BX807834, ZK-807834
分子量 526.49
分子式 C25H24F2N6O5
CAS No. 183305-24-0

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

DMSO: < 1mg/ml (insoluble)

TargetMol Calculator计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

TargetMol Library Books参考文献

1. Remko MR, et al. Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors. Molecules. 2016 Feb 4;21(2). 2. Chi L, et al. Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct factor Xa inhibitor. Pharmacology. 2002 Feb;64(2):76-83. 3. McClanahan TB, et l. The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis. Eur J Pharmacol. 2001 Dec 7;432(2-3):187-94. 4. Light DR, et al. Discovery of the factor Xa inhibitor, ZK 807834 (CI-1031). Curr Top Med Chem. 2001 Jun;1(2):121-36.
Rivaroxaban Impurity Rivaroxaban Edoxaban Zifaxaban O-Desmethyl apixaban sulfate sodium Eribaxaban Coumarin Heparin sodium salt

相关化合物库

该产品包含在如下化合物库中:
抑制剂库 已知活性化合物库 经典已知活性库

TargetMol Calculator剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

TargetMol Calculator 体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

Fidexaban 183305-24-0 Metabolism Factor Xa PD200022 CI-1031 BX-807834 PD 200022 PD-200022 ZK807834 CI1031 CI 1031 ZK 807834 BX807834 BX 807834 ZK-807834 Inhibitor inhibitor inhibit

 

TargetMol Loading
陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼